Aurora Doubles German Cannabis Output with EU-GMP Facility Expansion

  • Aurora completed a multi-million-dollar expansion of its Leuna, Germany facility, renaming it Aurora Horizon.
  • The expansion more than doubled the facility's annual flower output capacity.
  • The facility now incorporates Aurora's proprietary genetics and cultivation practices from Canada.
  • An expanded EU-GMP license was granted by the State Office for Social Affairs, Youth and Health of Saxony-Anhalt.
  • The expansion is expected to support job creation in the Saxony-Anhalt region.

Aurora's expansion in Germany underscores the strategic importance of local manufacturing in the European medical cannabis market. As one of only three domestic producers in Germany, Aurora is well-positioned to capitalize on the region's growing demand for high-quality, compliant products. The move also highlights the company's focus on supply chain resilience and operational efficiency, critical factors in a highly regulated industry.

Market Demand
How the increased capacity will position Aurora to meet growing medical cannabis demand in Germany and Europe.
Operational Efficiency
Whether Aurora can sustain the high-performance thresholds achieved at the expanded facility.
Regulatory Compliance
The pace at which Aurora can navigate and adapt to evolving EU-GMP regulations.